Dr. Laurence Klotz, Urologist, North York, ON

Academic summary: Undergraduate: University of Toronto, biology, 1971 to 1973 Medical training: University of Toronto, graduated 1977 Residency: University of Toronto, Gallie program in surgery, completed in 1983 Special Fellow in uro-oncology and tumour biology: Memorial Sloan Kettering Cancer Centre, New York, 1983-85 Appointments and affiliations: Chief, division of urology, Sunnybrook Professor, department of surgery, University of Toronto Former Chair, Canadian Uro-Oncology Group and NCIC GU Site Group Chair, Global GU Oncology Group Treasurer, Society of Urologic Oncology Chairman, World Uro Oncology Federation Member, American Association of Genito Urinary Surgeons President, Canadian Urology Association Elected Honorary Member, American Urological Association Education: MD, 1977, University of Toronto, Canada FRCS(C), 1983 Awards: Urology Care Foundation’s Richard Williams Prostate Cancer Research Excellence Award, 2016 Order of Canada, 2015 Society of Urologic Oncology Medal, 2014 Queen’s Jubilee Medal, 2013 Honorary Member, American Urological Association, 2012 Appointments and Affiliations: Affiliate scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Incumbent, Sunnybrook Prostate Cancer Research Chair Chairman, World Urologic Oncology Federation Editor-in-chief (founding), Canadian Journal of Urology Editor emeritus, (founding), Canadian Urology Association Journal Honourary member of board, Prostate Cancer Canada Past president, Urologic Research Society Research Foci: Micronutrients Prostate cancer prevention Active surveillance Research Summary: Prostate cancer, the most common human internal malignancy and the second most common cause of death in men, is likely highly preventable. The evidence for this is the 100-fold variation in incidence and mortality between races and regions, which is thought to be due, in part, to differences in dietary micronutrients. Dr. Klotz's laboratory has been studying the effect of selected micronutrients—particularly capsaicin, metformin and several isoflavanoids—in the prevention of prostate cancer. In a preclinical model, which spontaneously develops prostate cancer by eight months of age, his team has demonstrated that supplementing food with these micronutrients results in a dramatic and profound reduction in the development of these cancers. The major thrust of Dr. Klotz's research is to analyze the mechanisms by which these cancers are prevented. His team analyzes the effect of these antioxidants on gene expression and molecules, which regulate cell growth. They are also interested in the relationship between the androgen receptor, a critical component of prostate cancer biology, and the response to micronutrients. These studies will provide a scientific basis for the use of chemoprevention agents in prostate cancer. They will also provide some insight into the interaction between these agents. The studies will provide evidence as to whether patients with pre-neoplastic lesions of the prostate (i.e., PIN) benefit from micronutrients. This will have direct implications for men interested in preventing prostate cancer, and will provide a theoretical basis for optimizing the timing of initiation of preventive agents. Dr. Klotz also has a long interest in the conservative management of prostate cancer, and is the principal investigator on a number of clinical trials evaluating the role of various interventions and imaging studies in men on active surveillance. Selected Publications: See current publications list at PubMed. Related News and Stories: "Bespoke" prostate cancer treatment: Genomics and imaging tools are cracking the tough nut of prostate cancer, exposing which patients are most likely to get worse, and where tumours might be concealed (from SRI Magazine, 2016) A tapestry of clinical trials: High-impact findings: greater effectiveness, more precision, less harm and cost-conscious—this is what the cancer care of tomorrow looks like, emerging from the clinical trials of today (from SRI Magazine, 2016) Long-term Follow-up Indicates Active Surveillance Safe: Individualized approach for favourable risk prostate cancer shown to be safe and feasible in a 10- to 15-year time frame (November 17, 2009) Canadian Cancer Society Researcher of the Month : Dr. Laurence Klotz (September 2009) Image-Guided Ultrasound Targets Cancer: SRI scientists pioneer new treatment for prostate cancer (September 15, 2008) Spring Up: Eleven SRI researchers are recognized by a quartet of funding bodies (June 3, 2008) Reigning in the Radical - Laurence Klotz goes on active surveillance: A feature from Research Report 2004–2006

Dr. Laurence Klotz , Urologist North York Is in good standing with the College of Physicians and Surgeons of Canada, Dr. Laurence Klotz , Urologist North York is in good standing with the Canadian Urological Society and the Canadian Medical Association

Keywords: Benign Prostatic Hypertrophy, Benign prostatic hyperplasia (BPH) , Colon Cancer Screening & Treatment , Prostate Cancer, Hypothyroidism, Laparoscopic Surgery, Obesity Prostate Cancer treatment  

Dr. Laurence Klotz , Urologist North York 

Video by Dr. Laurence Klotz , Urologist North York : BPH treatment and surgical options

( Dr. Laurence Klotz, Urologist, North York, ON) is in good standing with the College of Physicians and Surgeons.

If you are looking for local services or  treatment froma local urologist   in the office or hospital from a Urologist, contact a provider such as ( Dr. Laurence Klotz ) to inquire if they are accepting patients or you need a referral.   Phone number to book an appointment 416-480-4673  ( Dr. Laurence Klotz ) Is in good standing with the College of Physicians and Surgeons ( Dr. Laurence Klotz ) Is in good standing with the Canadian Urological Society ( Dr. Laurence Klotz ) Is in good standing with the Canadian Medical Association

Keywords: Cancer: BPH, Cancer: Prostate Nutrition, Cancer: Breast Cancer, Cancer: Colon and Rectal Cancer Cancer: Lung Cancer, Cancer: Melanoma, Cancer: Ovarian Cancer, Cancer: Prostate Cancer

The speaker in the video may have no association with ( Dr. Laurence Klotz, Urologist North York, ON ). 
( Dr. Laurence Klotz, Urologist North York, ON ), may talk about some of the conditions and some of the treatment options shown on the videos. Always talk with your Local Urologist  about the information you learnt from the videos in regards to Male incontinence Contino® treatments and procedures the Local Urologist  could  perform and if they would be appropriate for you. Remember good information from your Local Urologist  is the corner stone to understanding your condition or disease.

Health Talks:

Sexual preservation for BPH prostate surgery

Urology Practice isa great pleace to start to look into If you’re experiencing symptoms of male incontinence, a local urologist can help. A local urologist can ask about your symptoms and recommend further testing or male incontinence treatment. Urethral inserts like Contino® are temporarily inserted into the urethra (the tube which carries urine to the outside of the body) to prevent or reduce bladder leakage. Damage to the kidneys can lead to swelling in the hands and ankles, high blood pressure, and other symptoms. 

Please contact ( Dr. Laurence Klotz, Urologist North York, ON ) to enquire if this health care provider is accepting new patients. Prostate Cancer NOW is part of the Now Health Network and its focus is on muscular and skeletal  conditions.  In summary, there are many different treatments for prostate cancer.  Identifying the best treatment will depend on your specific situation and your preference after discussion with your doctor. It is not true Asian men have the lowest risk of developing prostate cancer. African men have the highest risk. Often seeing a local urologist in Toronto can help. 

Medications like alpha blockers don't actually treat BPH, they treat the symptoms by relaxing the muscle around the urethra, so thereby reducing some of the resistance.

Sometimes we will add in a second line medication in order to try and shrink the prostate. These medications are called the five alpha reductase inhibitors. So we have Proscar or Avodart These are medications which work by lowering the conversion of testosterone within the prostate. Over a period of 6 to 12 months, this can shrink the prostate by around 20%.